Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer

• Main Authors: Masayuki Hiraki (Author), Junichi Nishimura (Author), Hidekazu Takahashi (Author), Xin Wu (Author), Yusuke Takahashi (Author), Masaaki Miyo (Author), Naohiro Nishida (Author), Mamoru Uemura (Author), Taishi Hata (Author), Ichiro Takemasa (Author), Tsunekazu Mizushima (Author), Jae-Won Soh (Author), Yuichiro Doki (Author), Masaki Mori (Author), Hirofumi Yamamoto (Author)
• Format: Book
• Published: Elsevier, 2015-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional releva...